NVCT
Nuvectis Pharma, Inc.
There isn't enough reported data to score NVCT yet.
NVCT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
NVCT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
NVCT PE Valuation
NVCT has no meaningful PE right now: it lost money over the past year.
NVCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| -- | |
| -- | |
| Limited | |
| Low |
Analysts expect NVCT's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
NVCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.89 | -$0.52 |
| Q2 2026 | -$1.31 | -$0.14 |
| Q1 2026 | -$1.31 | -$0.18 |
| Q4 2025 | -$1.32 | -$0.21 |
| Q3 2025 | -$1.37 | -$0.21 |
| Q2 2025 | -$1.17 | +$0.12 |
| Q1 2025 | -$1.13 | +$0.28 |
| Q4 2024 | -$1.11 | +$0.32 |
NVCT lost $1.89 per share over the past year, a bigger loss than the year before.
NVCT Quarterly Revenue
NVCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$25.3M | -$20.8M |
| Q2 2026 | -$4.5M | -$1.2M |
| Q1 2026 | -$6.5M | -$2.3M |
| Q4 2025 | -$4M | -$1.5M |
| Q3 2025 | -$4.5M | -$2.1M |
| Q2 2025 | -$3.4M | -$347K |
| Q1 2025 | -$4.2M | +$184K |
| Q4 2024 | -$2.5M | +$1.4M |
NVCT has burned cash in almost every quarter: −$40M over the past year, against −$15M the year before.
NVCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +26% | +6M shares |
| 1 year | +30% | +6.7M shares |
| 3 years | +94% | +14.3M shares |
| 5 years | +132% | +16.7M shares |
NVCT has 29M diluted shares, up 30% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
NVCT Net Leverage
NVCT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.2 | Neutral |
| Stochastic | 29.4 | Neutral |
NVCT's weekly RSI is 54 (neutral) and its Stochastic is 29 (neutral).
NVCT PE vs Healthcare Sector
NVCT has no meaningful PE right now: it lost money over the past year.
NVCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.2 | 0.2% above |
| 20 week MA | $20.8 | 2.6% below |
| 50 week MA | $14.0 | 44% above |
| 100 week MA | $10.7 | 89% above |
| 200 week MA | $10.3 | 97% above |
NVCT's trend is mixed: it's above four of its five weekly moving averages, and 97% above its 200-week average.
NVCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $3.25 | $7.74 | +138% |
| 2023 | $7.74 | $8.34 | +7.8% |
| 2024 | $8.34 | $5.22 | -37% |
| 2025 | $5.22 | $7.75 | +48% |
| 2026 YTD | $7.75 | $20.2 | +161% |
NVCT has finished higher in three of the last four years. It's up 161% so far in 2026.